Analysis: HIV generics under threat from tighter patenting rules

VIENNA Monday, August 02, 2010 (IRIN) - Most of the estimated 5.2 million people worldwide on antiretroviral (ARV) treatment are taking generic versions manufactured primarily in India, but tighter global intellectual property rights and trade rules could shut down "the pharmacy of the developing world".